The first trials did not demonstrate effectiveness beyond placebo. So the FDA allowed a third trial which apparently did, at least a little.
The physician, meanwhile, depends on the information provided by medical science, usually in the form of materials from the pharma firm that markets the product.
The increased incidence of depression, anxiety, and other psychiatric symptoms linked to OUD may also help to account for high rates of relapse among patients, post-treatment, versus other substance disorders.
My concern is that these same hallucinogens have a pronounced tendency to escape the research environment and find their way out into the streets
In the absence of complaints, the prescriber can be tempted to assume things are going well, when in fact they aren’t.
Patients with severe substance disorders may experience depression as a result of the cumulative effects of their substance use.
It’s an illness that at different times seems to respond to everything and nothing. As in ‘everything works for someone, and nothing works for everyone.’
The better we understand the origins of a depressed mood, the more likely we are to come up with an effective remedy.